With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts
You may also be interested in...
Sanofi Sees China Growth Bolstered By County Hospitals Push
Thousands of county hospitals offer significant growth opportunities for the next 10 years, says Sanofi SVP Jean-Luc Lowinski, but adds the challenges at building the market are unique for multinational drug manufacturers in China.
Asia Spotlight: GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts
China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.
GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts
China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.